Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
5Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
VYNE Therapeutics Inc. (VYNE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
1Distinct source URLs
6High confidence
0.776Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
VYNE Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
TAY
TAY
90%
The Company will pay tiered royalties to Tay on net sales of such licensed products by the Company, its affiliates, or sublicensees
CUTIA-THERAPEUTICS-HK-LIMITED
CUTIA-THERAPEUTICS-HK-LIMITED
80%
the license agreement with Cutia Therapeutics (HK) Limited
Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operations. Our human capital management objectives include, as applicable, identifying, r…
Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…
Reciprocal relationship from SLGL graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from SLGL graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from SLGL g…
Reciprocal relationship from FBIO graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from FBIO graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from FBIO g…
Reciprocal relationship from DERM graph: Reciprocal relationship from VYNE graph: Reciprocal relationship from DERM graph: er serious labor problems that have materially impeded our business operatio…
Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a…
Reciprocal relationship from SLGL graph: clinical site initiation and recruiting clinical site investigators and clinical site staff; • increased rates of patients withdrawing from our clinical trial…
FOAMIX-PHARMACEUTICALS-LTD
FOAMIX-PHARMACEUTICALS-LTD
62%
O Pharma A/S ("LEO Pharma"). Formulation and use patents for Finacea foam currently expire in 2027 and 2029, respectively, but may experience an earlier loss of exclusivity due to generic entry. For …
VYNE Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
VYNE-DEBT-13485
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
VYNE-DEBT-13484
Warrants outstanding: 27509
90%
xbrl warrant detail from xbrl 2026-03-31.
VYNE Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for VYNE Therapeutics Inc..
VYNE Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
VYNE-OWNER-ANSON-FUNDS-MANAGEMENT-LP
Anson Funds Management LP
90%
13F overlay lists Anson Funds Management LP as top holder; 46 tracked holders.
VYNE Therapeutics Inc. Extended Supply Chain Network
